Overview

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is reported to be able to improve the outcomes for elderly acute myeloid leukemia (AML) in complete remission (CR). At present, the best conditioning regimen for elderly AML in CR remains in discussion. In this prospective study, the safety and efficacy of Dec+Flu+Bu myeloablative conditioning regimens in patients with elderly AML in CR undergoing allo-HSCT are evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Guangzhou First People's Hospital
Peking University People's Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Third Affiliated Hospital, Sun Yat-Sen University
Zhujiang Hospital
Treatments:
Azacitidine
Busulfan
Decitabine
Fludarabine
Fludarabine phosphate
Vidarabine